Biomarkers Improve Clinical Outcome Predictors of Mortality Following Non-Penetrating Severe Traumatic Brain Injury

Neurocritical Care

Volumn 22, Issue 1, 2015, Pages 52-64

  Papa, Linda ^a   Robertson, Claudia S ^b   Wang, Kevin K W ^c   Brophy, Gretchen M ^d   Hannay, H Julia ^e   Heaton, Shelley ^f   Schmalfuss, Ilona ^c   Gabrielli, Andrea ^c   Hayes, Ronald L ^g   Robicsek, Steven A ^c  

^a ORLANDO REGIONAL MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^e UNIVERSITY OF HOUSTON   (United States)

^f UNIVERSITY OF FLORIDA   (United States)

^g BANYAN BIOMARKERS INC   (United States)

Author keywords

Alpha spectrin breakdown products (SBDPs); Biomarkers; Microtubual associated protein (MAP 2); Mortality; S100B; Severe traumatic brain injury; Ubiquitin C terminal hydrolase (UCH L1)

Indexed keywords

BIOLOGICAL MARKER; MAP2 PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN;

ADOLESCENT; ADULT; AGED; BRAIN INJURY; CEREBROSPINAL FLUID; FEMALE; GLASGOW COMA SCALE; HUMAN; MALE; MIDDLE AGED; MORTALITY; PROGNOSIS; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; BRAIN INJURIES; FEMALE; GLASGOW COMA SCALE; HUMANS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; MODELS, STATISTICAL; PROGNOSIS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84930613419     PISSN: 15416933     EISSN: 15560961     Source Type: Journal    
DOI: 10.1007/s12028-014-0028-2     Document Type: Article

References (62)

1. Corrigan JD, Selassie AW, Orman JA. The epidemiology of traumatic brain injury. J Head Trauma Rehabil. 2010;25(2):72–80.
2. Faul M, Xu L, Wald MM, et al. Traumatic Brain Injury in the United States. In: Emergency Department Visits, Hospitalizations and Deaths 2002–2006. Atlanta (GA): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2010.
3. Gaetz M. The neurophysiology of brain injury. Clin Neurophysiol. 2004;115(1):4–18.
4. Pineda JA, Wang KK, Hayes RL. Biomarkers of proteolytic damage following traumatic brain injury. Brain Pathol. 2004;14(2):202–9.
5. Haskins WE, Kobeissy FH, Wolper RA, et al. Rapid discovery of putative protein biomarkers of traumatic brain injury by SDS-PAGE-capillary liquid chromatography-tandem mass spectrometry. J Neurotrauma. 2005;22(6):629–44.
6. MisslerU. S-100 protein and neuron-specific enolase concentrations in blood as indicators of infarction volume and prognosis in acute ischemic stroke. Stroke. 1997;28:1956–60.
7. Ytrebo LMNG, Korvald C, et al. Renal elimination of protein S-100beta in picgs with acute encephalopathy. Scand J Clin Lab Invest. 2001;61:217–25.
8. Jonsson HJP, Hoglund P, Alling C, Blomquist S. The elimination of S-100b and renal function after cardiac surgery. J Cardiothorac Vasc Aneth. 2000;14:698–701.
9. Usui AKK, Abe T, Murase M, Tanaka M, Takeuchi E. S-100ao protein in blood and urine during open-heart surgery. Clin Chem. 1989;35:1942–4.
10. Raabe A, Grolms C, Seifert V. Serum markers of brain damage and outcome prediction in patients after severe head injury. Br J Neurosurg. 1999;13(1):56–9.
11. Haimoto H, Hosoda S, Kato K. Differential distribution of immunoreactive S100-a and S100-b proteins in normal nonnervous human tissues. Lab Invest. 1987;57:489–98.
12. Woertgen C, Rothoerl RD, Holzschuh M, et al. Comparison of serial S-100 and NSE serum measurements after severe head injury. Acta Neurochir (Wien). 1997;139(12):1161–4 discussion 1165.
13. Romner B, Ingebrigtsen T, Kongstad P, et al. Traumatic brain damage: serum S-100 protein measurements related to neuroradiological findings. J Neurotrauma. 2000;17(8):641–7.
14. Korfias S, Stranjalis G, Boviatsis E, et al. Serum S-100B protein monitoring in patients with severe traumatic brain injury. Intensive Care Med. 2007;33(2):255–60.
15. Vos PE, Jacobs B, Andriessen TM, et al. GFAP and S100B are biomarkers of traumatic brain injury: an observational cohort study. Neurology. 2010;75(20):1786–93.
16. Berger RP, Pierce MC, Wisniewski SR, et al. Serum S100B concentrations are increased after closed head injury in children: a preliminary study. J Neurotrauma. 2002;19(11):1405–9.
17. Bw M. A soluble protein characteristic of the nervous system. Biochem Biophys Res Commun. 1965;19:739–44.
18. Donato R. Functional roles of S100 proteins, calcium-binding proteins of the EF-hand type. Biochim Biophys Acta. 1999;1450:191–231.
19. Cooper E. Neuron-specific enolase. Int J Biol Markers. 1994;4:205–10.
20. Yamazaki Y, Yada K, Morii S, et al. Diagnostic significance of serum neuron-specific enolase and myelin basic protein assay in patients with acute head injury. Surg Neurol. 1995;43(3):267 discussion 270–261.
21. de Kruijk JR, Leffers P, Menheere PP, et al. S-100B and neuron-specific enolase in serum of mild traumatic brain injury patients. A comparison with health controls. Acta Neurol Scand. 2001;103(3):175–9.
22. Naeimi ZS, Weinhofer A, Sarahrudi K, et al. Predictive value of S-100B protein and neuron specific-enolase as markers of traumatic brain damage in clinical use. Brain Inj. 2006;20(5):463–8.
23. Berger RP, Adelson PD, Pierce MC, et al. Serum neuron-specific enolase, S100B, and myelin basic protein concentrations after inflicted and noninflicted traumatic brain injury in children. J Neurosurg. 2005;103(1 Suppl):61–8.
24. Wang KK, Ottens AK, Liu MC, et al. Proteomic identification of biomarkers of traumatic brain injury. Expert Rev Proteomics. 2005;2(4):603–14.
25. Berger RP, Beers SR, Richichi R, et al. Serum biomarker concentrations and outcome after pediatric traumatic brain injury. J Neurotrauma. 2007;24(12):1793–801.
26. Beers SR, Berger RP, Adelson PD. Neurocognitive outcome and serum biomarkers in inflicted versus non-inflicted traumatic brain injury in young children. J Neurotrauma. 2007;24(1):97–105.
27. Pineda JA, Lewis SB, Valadka AB, et al. Clinical significance of alphaII-spectrin breakdown products in cerebrospinal fluid after severe traumatic brain injury. J Neurotrauma. 2007;24(2):354–66.
28. Brophy GM, Pineda JA, Papa L, et al. alphaII-Spectrin breakdown product cerebrospinal fluid exposure metrics suggest differences in cellular injury mechanisms after severe traumatic brain injury. J Neurotrauma. 2009;26(4):471–9.
29. Mondello S, Robicsek SA, Gabrielli A, et al. alphaII-spectrin breakdown products (SBDPs): diagnosis and outcome in severe traumatic brain injury patients. J Neurotrauma. 2010;27(7):1203–13.
30. Berger RP, Hayes RL, Richichi R, et al. Serum concentrations of ubiquitin C-terminal hydrolase-L1 and alphaII-spectrin breakdown product 145 kDa correlate with outcome after pediatric TBI. J Neurotrauma. 2012;29(1):162–7.
31. Siman R, Toraskar N, Dang A, et al. A panel of neuron-enriched proteins as markers for traumatic brain injury in humans. J Neurotrauma. 2009;26(11):1867–77.
32. Papa L, Akinyi L, Liu MC, et al. Ubiquitin C-terminal hydrolase is a novel biomarker in humans for severe traumatic brain injury. Crit Care Med. 2010;38(1):138–44.
33. Brophy GM, Mondello S, Papa L, et al. Biokinetic Analysis of Ubiquitin C-Terminal Hydrolase-L1 (UCH-L1) in Severe Traumatic Brain Injury Patient Biofluids. J Neurotrauma. 2011;28(6):861–70.
34. Papa L, Lewis LM, Silvestri S, et al. Serum levels of ubiquitin C-terminal hydrolase distinguish mild traumatic brain injury from trauma controls and are elevated in mild and moderate traumatic brain injury patients with intracranial lesions and neurosurgical intervention. J Trauma Acute Care Surg. 2012;72(5):1335–44.
35. Mondello S, Gabrielli A, Catani S, et al. Increased levels of serum MAP-2 at 6-months correlate with improved outcome in survivors of severe traumatic brain injury. Brain Inj. 2012;26(13–14):1629–35.
36. Steyerberg EW, Mushkudiani N, Perel P, et al. Predicting outcome after traumatic brain injury: development and international validation of prognostic scores based on admission characteristics. PLoS Med. 2008;5(8):e165 discussion e165.
37. Zhang Z, Mondello S, Kobeissy FH, et al. Protein biomarkers for traumatic and ischemic brain injury: from Bench to Bedside. Transl Stroke Res. 2011;2(4):455–62.
38. Papa L, Robinson G, Oli M, et al. Use of Biomarkers for Diagnosis and Management of Traumatic Brain Injury Patients. Expert Opin Med Diagn. 2008;2(8):937–45.
39. Papa L. Exploring the Role of Biomarkers for the Diagnosis and Management of Traumatic Brain Injury Patients. In: Man TK, Flores RJ, editors. Proteomics - Human Diseases and Protein Functions. 1st ed. Veinna: In Tech Open Access Publisher; 2012.
40. Perel P, Arango M, Clayton T, et al. Predicting outcome after traumatic brain injury: practical prognostic models based on large cohort of international patients. BMJ. 2008;336(7641):425–9.
41. Xiong H, Liang WL, Wu XR. Pathophysiological alterations in cultured astrocytes exposed to hypoxia/reoxygenation. Sheng Li Ke Xue Jin Zhan. 2000;31(3):217–21.
42. Goodman SR, Zimmer WE, Clark MB, et al. Brain spectrin: of mice and men. Brain Res Bull. 1995;36(6):593–606.
43. Riederer BM, Zagon IS, Goodman SR. Brain spectrin(240/235) and brain spectrin(240/235E): two distinct spectrin subtypes with different locations within mammalian neural cells. J Cell Biol. 1986;102(6):2088–97.
44. Wang KK, Posmantur R, Nath R, et al. Simultaneous degradation of alphaII- and betaII-spectrin by caspase 3 (CPP32) in apoptotic cells. J Biol Chem. 1998;273(35):22490–7.
45. McGinn MJ, Kelley BJ, Akinyi L, et al. Biochemical, structural, and biomarker evidence for calpain-mediated cytoskeletal change after diffuse brain injury uncomplicated by contusion. J Neuropathol Exp Neurol. 2009;68(3):241–9.
46. Jackson P, Thompson RJ. The demonstration of new human brain-specific proteins by high-resolution two-dimensional polyacrylamide gel electrophoresis. J Neurol Sci. 1981;49(3):429–38.
47. Czeiter E, Mondello S, Kovacs N, et al. Brain injury biomarkers may improve the predictive power of the IMPACT outcome calculator. J Neurotrauma. 2012;29(9):1770–8.
48. da Rocha AB, Schneider RF, de Freitas GR, et al. Role of serum S100B as a predictive marker of fatal outcome following isolated severe head injury or multitrauma in males. Clin Chem Lab Med. 2006;44(10):1234–42.
49. Chen LJ, Wang YJ, Tseng GF. Compression alters kinase and phosphatase activity and tau and MAP2 phosphorylation transiently while inducing the fast adaptive dendritic remodeling of underlying cortical neurons. J Neurotrauma. 2010;27(9):1657–69.
50. Diez-Guerra FJ, Avila J. Rapid dephosphorylation of microtubule-associated protein 2 in the rat brain hippocampus after pentylenetetrazole-induced seizures. Eur J Biochem. 1993;215(1):181–7.
51. Posmantur RM, Kampfl A, Taft WC, et al. Diminished microtubule-associated protein 2 (MAP2) immunoreactivity following cortical impact brain injury. J Neurotrauma. 1996;13(3):125–37.
52. Kobeissy FH, Ottens AK, Zhang Z, et al. Novel differential neuroproteomics analysis of traumatic brain injury in rats. Mol Cell Proteomics. 2006;5(10):1887–98.
53. Khan SH, Kureshi IU, Mulgrew T, et al. Comparison of percutaneous ventriculostomies and intraparenchymal monitor: a retrospective evaluation of 156 patients. Acta Neurochir Suppl. 1998;71:50–2.
54. Iberti TJ, Leibowitz AB, Papadakos PJ, et al. Low sensitivity of the anion gap as a screen to detect hyperlactatemia in critically ill patients. Crit Care Med. 1990;18(3):275–7.
55. Hunter CL, Silvestri S, Dean M, et al. End-tidal carbon dioxide is associated with mortality and lactate in patients with suspected sepsis. Am J Emerg Med. 2013;31(1):64–71.
56. Lingsma HF, Roozenbeek B, Li B, et al. Large between-center differences in outcome after moderate and severe traumatic brain injury in the international mission on prognosis and clinical trial design in traumatic brain injury (IMPACT) study. Neurosurgery. 2011;68(3):601–7 discussion 607–608.
57. Ferguson I, Lewis L, Papa L. Neuronal Biomarkers may require age-adjusted norms. Ann Emerg Med. 2011;58(4):S213.
58. Liu MC, Akinyi L, Scharf D, et al. Ubiquitin C-terminal hydrolase-L1 as a biomarker for ischemic and traumatic brain injury in rats. Eur J Neurosci. 2010;31(4):722–32.
59. Mondello S, Papa L, Buki A, et al. Neuronal and glial markers are differently associated with computed tomography findings and outcome in patients with severe traumatic brain injury: a case control study. Crit Care. 2011;15(3):R156.
60. Mondello S, Gabrielli A, Catani S, et al. Increased levels of serum MAP-2 at 6 months correlate with improved outcome in survivors of severe traumatic brain injury. Brain Inj. 2012;26(13-14):1629–35.
61. Dutta S, Chiu YC, Probert AW, et al. Selective release of calpain produced alphalI-spectrin (alpha-fodrin) breakdown products by acute neuronal cell death. Biol Chem. 2002;383(5):785–91.
62. Nath R, Davis M, Probert AW, et al. Processing of cdk5 activator p35 to its truncated form (p25) by calpain in acutely injured neuronal cells. Biochem Biophys Res Commun. 2000;274(1):16–21.